volume 29 issue 3 pages 574-577

Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy

Publication typeJournal Article
Publication date2013-12-01
scimago Q2
wos Q2
SJR0.829
CiteScore4.9
Impact factor2.3
ISSN15255050, 15255069
Neurology
Neurology (clinical)
Behavioral Neuroscience
Abstract
Severe childhood epilepsies are characterized by frequent seizures, neurodevelopmental delays, and impaired quality of life. In these treatment-resistant epilepsies, families often seek alternative treatments. This survey explored the use of cannabidiol-enriched cannabis in children with treatment-resistant epilepsy. The survey was presented to parents belonging to a Facebook group dedicated to sharing information about the use of cannabidiol-enriched cannabis to treat their child's seizures. Nineteen responses met the following inclusion criteria for the study: a diagnosis of epilepsy and current use of cannabidiol-enriched cannabis. Thirteen children had Dravet syndrome, four had Doose syndrome, and one each had Lennox-Gastaut syndrome and idiopathic epilepsy. The average number of antiepileptic drugs (AEDs) tried before using cannabidiol-enriched cannabis was 12. Sixteen (84%) of the 19 parents reported a reduction in their child's seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported a 25-60% seizure reduction. Other beneficial effects included increased alertness, better mood, and improved sleep. Side effects included drowsiness and fatigue. Our survey shows that parents are using cannabidiol-enriched cannabis as a treatment for their children with treatment-resistant epilepsy. Because of the increasing number of states that allow access to medical cannabis, its use will likely be a growing concern for the epilepsy community. Safety and tolerability data for cannabidiol-enriched cannabis use among children are not available. Objective measurements of a standardized preparation of pure cannabidiol are needed to determine whether it is safe, well tolerated, and efficacious at controlling seizures in this pediatric population with difficult-to-treat seizures.
Found 
Found 

Top-30

Journals

5
10
15
20
25
Epilepsy and Behavior
23 publications, 8.19%
Epilepsia
6 publications, 2.14%
Frontiers in Pharmacology
5 publications, 1.78%
Frontiers in Neurology
4 publications, 1.42%
New England Journal of Medicine
3 publications, 1.07%
Cannabis and Cannabinoid Research
3 publications, 1.07%
Journal of Child Neurology
3 publications, 1.07%
Experimental Neurology
3 publications, 1.07%
Pediatric Neurology
3 publications, 1.07%
Seizure : the journal of the British Epilepsy Association
3 publications, 1.07%
Journal of Paediatrics and Child Health
3 publications, 1.07%
Paediatrics and Child Health
3 publications, 1.07%
Journal of Pharmacology and Experimental Therapeutics
2 publications, 0.71%
AAP Grand Rounds
2 publications, 0.71%
Journal of Developmental and Behavioral Pediatrics
2 publications, 0.71%
CMAJ Open
2 publications, 0.71%
Frontiers in Behavioral Neuroscience
2 publications, 0.71%
International Journal of Molecular Sciences
2 publications, 0.71%
Paediatric Drugs
2 publications, 0.71%
Current Treatment Options in Neurology
2 publications, 0.71%
Molecular Neurobiology
2 publications, 0.71%
Neurotherapeutics
2 publications, 0.71%
CNS Drugs
2 publications, 0.71%
Neuropharmacology
2 publications, 0.71%
Pharmacology and Therapeutics
2 publications, 0.71%
Medical Journal of Australia
2 publications, 0.71%
Journal of Pediatric Pharmacology and Therapeutics
2 publications, 0.71%
Canadian Journal of Neurological Sciences
2 publications, 0.71%
Journal of Pediatric Neurology
2 publications, 0.71%
5
10
15
20
25

Publishers

10
20
30
40
50
60
70
80
Elsevier
73 publications, 25.98%
Springer Nature
36 publications, 12.81%
Wiley
26 publications, 9.25%
Cambridge University Press
26 publications, 9.25%
Frontiers Media S.A.
14 publications, 4.98%
MDPI
11 publications, 3.91%
Ovid Technologies (Wolters Kluwer Health)
9 publications, 3.2%
SAGE
9 publications, 3.2%
Taylor & Francis
8 publications, 2.85%
Oxford University Press
5 publications, 1.78%
Mary Ann Liebert
4 publications, 1.42%
Cold Spring Harbor Laboratory
4 publications, 1.42%
Massachusetts Medical Society
3 publications, 1.07%
American Academy of Pediatrics
3 publications, 1.07%
CMA Impact Inc.
3 publications, 1.07%
BMJ
3 publications, 1.07%
American Society for Pharmacology and Experimental Therapeutics
2 publications, 0.71%
Bentham Science Publishers Ltd.
2 publications, 0.71%
American Chemical Society (ACS)
2 publications, 0.71%
Pediatric Pharmacology Advocacy Group, Inc.
2 publications, 0.71%
Hindawi Limited
2 publications, 0.71%
Georg Thieme Verlag KG
2 publications, 0.71%
Emerald
1 publication, 0.36%
F1000 Research
1 publication, 0.36%
Impact Journals
1 publication, 0.36%
American Epilepsy Society
1 publication, 0.36%
Japan Society for Analytical Chemistry
1 publication, 0.36%
American Society for Biochemistry and Molecular Biology
1 publication, 0.36%
Korean Epilepsy Society
1 publication, 0.36%
10
20
30
40
50
60
70
80
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
281
Share
Cite this
GOST |
Cite this
GOST Copy
Porter B., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy // Epilepsy and Behavior. 2013. Vol. 29. No. 3. pp. 574-577.
GOST all authors (up to 50) Copy
Porter B., Jacobson C. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy // Epilepsy and Behavior. 2013. Vol. 29. No. 3. pp. 574-577.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.yebeh.2013.08.037
UR - https://doi.org/10.1016/j.yebeh.2013.08.037
TI - Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy
T2 - Epilepsy and Behavior
AU - Porter, Brenda
AU - Jacobson, Catherine
PY - 2013
DA - 2013/12/01
PB - Elsevier
SP - 574-577
IS - 3
VL - 29
PMID - 24237632
SN - 1525-5050
SN - 1525-5069
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2013_Porter,
author = {Brenda Porter and Catherine Jacobson},
title = {Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy},
journal = {Epilepsy and Behavior},
year = {2013},
volume = {29},
publisher = {Elsevier},
month = {dec},
url = {https://doi.org/10.1016/j.yebeh.2013.08.037},
number = {3},
pages = {574--577},
doi = {10.1016/j.yebeh.2013.08.037}
}
MLA
Cite this
MLA Copy
Porter, Brenda, and Catherine Jacobson. “Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy.” Epilepsy and Behavior, vol. 29, no. 3, Dec. 2013, pp. 574-577. https://doi.org/10.1016/j.yebeh.2013.08.037.